Adagio Medical Holdings, Inc. is a commercial stage medical device company. It is focused on developing proprietary Ultra-Low Temperature Cryoablation technology that creates contiguous, transmural lesions to treat cardiac arrhythmias, with an emphasis on ventricular tachycardia. It is developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for the treatment of ventricular arrhythmia.
Símbolo de cotizaciónADGM
Nombre de la empresaAdagio Medical Holdings Inc
Fecha de salida a bolsaFeb 26, 2021
Director ejecutivoUsen (Todd)
Número de empleados86
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 26
Dirección26051 Merit Circle
CiudadLAGUNA HILLS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92653
Teléfono19493481188
Sitio Web
Símbolo de cotizaciónADGM
Fecha de salida a bolsaFeb 26, 2021
Director ejecutivoUsen (Todd)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos